20
Participants
Start Date
April 1, 2024
Primary Completion Date
March 1, 2025
Study Completion Date
March 1, 2025
LTC004+regorafenib
LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER